北京若生智能科技有限公司
Drug Database
LA

lamotrigine orally disintegrating tablet (lamotrigine ODT / lamictal ODT / EUR1048)

✓ Approved

Adare Pharma Solutions · SCN1A · 小分子

什么是 lamotrigine orally disintegrating tablet？

lamotrigine orally disintegrating tablet 是一种小分子，由Adare Pharma Solutions研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名lamotrigine ODT, lamictal ODT, EUR1048
公司Adare Pharma Solutions
药物类别小分子
分子靶点SCN1A, SCN2A, SCN3A
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Adare Pharma Solutions

作用机制

分子靶点

lamotrigine orally disintegrating tablet 作用于 3 个分子靶点：

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lamotrigine orally disintegrating tablet 针对 4 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersLennox-Gastaut syndrome✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Nervous system disordersPartial seizures✓ Approved

相关研究文献

PubMedGels (Basel, Switzerland)2026-10-26

Turmeric-Loaded Type A Gelatin Hydrogels: In Vitro Assessment for Oral Wound Management Applications.

Gutierrez-Jimenez Yareth Idalia Ayerim YIA, Garcia-Contreras Rene R, Serrano-Diaz Paloma Netzayeli PN, Flores-Arriaga Juan Carlos JC et al.

Oral surgical wounds may benefit from local biomaterials capable of delivering bioactive compounds while remaining compatible with gingival cells. This study evaluated type A gelatin hydrogels containing turmeric powder (1.5, 3.1, or 12.5 mg per preparation) and a separate series prepared with a 25 mg/mL turmeric stock in dimethyl sulfoxide (DMSO). The hydrogels were assessed for macroscopic integrity, supernatant absorbance, MTT responses in human gingival fibroblasts (HGFs), prostaglandin E2 (PGE2), and exploratory microbial response against Staphylococcus aureus and Candida albicans. Powder-loaded matrices lost macroscopic integrity within approximately 45 min in PBS and 30 min in trypsin. Powder-loaded formulations generally produced MTT signals near control values, whereas several DMSO-stock formulations showed lower signals at later exposures. PGE2 did not show consistent dose-dependent suppression after normalization of the corresponding MTT-derived relative metabolic signal. Agar diffusion showed an approximate 2.4 mm clearance beyond the specimen edge against S. aureus for the 1.5 mg formulation and none against C. albicans; the gelatin control also showed visible clearance, and higher turmeric loadings did not produce measurable zones. Colony recovery decreased across the DMSO-stock formulations, but most plate counts were below the conventional countable range and were therefore interpreted descriptively. Overall, the findings provide an early in vitro characterization of rapidly disintegrating gelatin-turmeric hydrogels and identify matrix stability and assay limitations as major constraints that require further validation.

PMID 42929961
阅读全文 →
PubMedTheScientificWorldJournal2026-10-26

Comparative Quality Evaluation of Marketed Cefixime Trihydrate Tablet Brands Available in Bangladesh.

Islam Ariful A, Shanto Shahriar Alam SA, Akter Sumaiya S, Nashrah Antara A et al.

In low- and middle-income countries, antibiotic resistance is rising rapidly because of poor medication adherence, polypharmacy, and weak regulatory enforcement, while substandard and counterfeit medicines further accelerate resistance. Cefixime trihydrate, a broad-spectrum third-generation cephalosporin, is a widely used and frequently prescribed antibiotic in Bangladesh. This study evaluated quality attributes, including % drug content and % drug release, of eight commonly prescribed cefixime 200 mg tablet brands and compared them with the innovator-equivalent brand. Chromatographic separation was performed on a reversed-phase C18 column with UV detection at 282 nm (column temperature 30°C; run time 8 min), using methanol and 0.01 M KH2PO4 buffer (pH 4.5) at 1 mL/min. Dissolution studies were conducted using a USP Apparatus 2, and antimicrobial activity was assessed via the Kirby-Bauer disc diffusion method. All nine brands met USP potency standards (90%-110%) and dissolution criteria (≥ 75% drug release within 45 min). A one-way ANOVA with Dunnett's test (α = 0.05, two-tailed; critical value = 2.731) revealed significant differences between Tab. A, Tab. E, and Tab. F and the reference brand at 45 min. However, among local brands, seven out of eight (87.5%) complied with the FDA-recommended difference factor (f1) and similarity (f2) factor criteria. Zone of inhibition studies showed good antimicrobial activity across most of the brands at 5 μg disc load. Seven out of the eight local brands met the f1/f2 similarity criteria relative to the reference, indicating comparable in vitro dissolution behavior, whereas one brand (Tab. C) did not. These results emphasize the need for continuous quality surveillance to ensure therapeutic equivalence and combat antimicrobial resistance.

PMID 42929366
阅读全文 →
PubMedThe New England journal of medicine2026-10-26

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

Skoulidis Ferdinandos F, Ahn Myung-Ju MJ, Gadgeel Shirish S, Popat Sanjay S et al.

Divarasib, a next-generation, oral KRAS G12C inhibitor, is more potent and selective in vitro than the first-generation KRAS G12C inhibitors sotorasib and adagrasib. In this phase 3, international, open-label trial, patients with previously treated KRAS G12C-mutated advanced or metastatic non-small-cell lung cancer (NSCLC) were randomly assigned to receive divarasib orally at a dose of 400 mg once daily or control treatment (sotorasib orally at a dose of 960 mg once daily or adagrasib orally at a dose of 600 mg twice daily) until the occurrence of disease progression, unacceptable adverse events, loss of clinical benefit, withdrawal of consent, death, or trial termination. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included overall survival, confirmed overall response, duration of response, patient-reported outcomes, and safety. A total of 338 patients received divarasib (167 patients) or control treatment (171 patients; 156 received sotorasib and 15 received adagrasib). The median follow-up was 14.3 months. The median progression-free survival was 9.8 months with divarasib and 5.7 months with control treatment (hazard ratio for disease progression or death, 0.58; 95% confidence interval [CI], 0.44 to 0.76; P<0.001). The median overall survival was 17.7 months with divarasib and 12.0 months with control treatment (hazard ratio for death, 0.56; 95% CI, 0.41 to 0.78; P<0.001). Of the 328 patients who could be evaluated for response, a confirmed response occurred in 58.4% in the divarasib group and in 32.3% in the control group. The median duration of response was 11.9 months with divarasib and 6.9 months with control treatment. Fewer grade 3 or 4 treatment-related adverse events were noted with divarasib (24.6%) than with control treatment (34.5%). Among patients with previously treated KRAS G12C-mutated advanced or metastatic NSCLC, divarasib led to significantly longer progression-free and overall survival than control treatment. (Supported by F. Hoffmann-La Roche; Krascendo 1 ClinicalTrials.gov number, NCT06497556.).

PMID 42929675
阅读全文 →
PubMedJournal of medical case reports2026-10-26

High-dose regular insulin as a potential rescue therapy in severe aluminum phosphide poisoning: a case report.

Sedaghattalab Moslem M, Akbari Ghaidafeh G

Aluminum phosphide (rice tablet) can cause cardiocirculatory collapse and has negative cardiac inotropic effect. Positive inotropic effect of insulin on the cardiac myocytes is through calcium flux. Insulin increases the intramyocytes calcium concentration by increasing conductance of calcium through the L-type calcium channels and by increasing intramyocytes concentration of cyclic adenosine monophosphate. In addition to increasing the intramyocytes calcium level, insulin also enhances the responsiveness of the cardiac cells to calcium. High-dose insulin is a potential therapy for hypodynamic and hypotensive septic shock due to its positive inotropic qualities. In this paper, a critical aluminum phosphide poisoning patient (a 25-year-old Iranian young woman), presented with mixed severe metabolic acidosis and respiratory alkalosis, tachypnea, tachycardia, and hypotension. In contrast to our previous experiences that ingestion of aluminum phosphide tablets associated with multiple organ failure and severe shock in approximately all critical poisoning patients, early initiation of high-dose intravenous regular insulin for this patient prevented multiorgan dysfunction and death. Treatment with high-dose intravenous insulin associated with IV fluids, sodium bicarbonate, hydrocortisone, potassium, dextrose therapy and supportive care resolved completely signs and symptoms of patient after 3 days in ICU. High-dose intravenous regular insulin may be act as a rescue therapy for aluminum phosphide poisoning patients. While this single case suggests a potential benefit, further studies are required to confirm these findings.

PMID 42928247
阅读全文 →
PubMedVeterinary surgery : VS2026-10-26

Trazodone administration does not affect platelet concentration or function in horses.

Phillips Nicole A I NAI, Goggs Robert R, Pinn-Woodcock Toby L TL, Colbath Aimee C AC

To determine the effect of a clinically relevant dose of trazodone on platelet count and function in healthy horses. Prospective, controlled, cross-over study. Ten healthy horses. Horses were administered either 7 mg/kg trazodone orally in corn syrup or an equal amount of corn syrup (control), every 12 h for 2 weeks. After 2 weeks, horses underwent at least a 2-week washout period before being administered the alternate treatment (trazodone or control). Blood was collected before the first treatment administration (day 0) and after 2 weeks of treatment for each phase of the study. Complete blood cell counts, platelet function assays, and plasma trazodone concentrations were assessed. Data were analyzed using repeated measures ANOVA with significance set at p < .05. No differences in platelet count or tests of platelet function were observed at any time point after trazodone or control treatment. There were no adverse effects of trazodone administration appreciated on repeat physical examinations or daily ataxia scoring. No inhibitory effects of trazodone on platelet function in horses were detected. This study suggests administration of oral trazodone at 7 mg/kg prior to surgery is unlikely to impair platelet function in healthy horses.

PMID 42928479
阅读全文 →
PubMedMedComm2026-10-26

Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial.

Fang Wentao W, Zhou Caicun C, Wang Changlu C, Wu Kailiang K et al.

Advanced thymic carcinoma is a rare, aggressive malignancy with limited treatment options after chemotherapy failure. This randomized, double-blind, placebo-controlled trial (AL3810-202) aimed to evaluate lucitanib, a novel, orally potent tyrosine kinase inhibitor targeting VEGFR1‒3, FGFR1‒3, and PDGFRα/β in patients with advanced thymic carcinoma progressing after chemotherapy. Sixty-eight patients were randomized (2:1) to receive 10 mg lucitanib daily (n = 46) or placebo (n = 22). Although this study did not meet its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS) (median 5.8 vs. 3.7 months; hazard ratio [HR]: 0.60; p = 0.1050), the prespecified log-rank test may have underestimated the treatment effect due to an observed non-proportional hazards pattern. Subsequent restricted mean survival time analysis demonstrated a statistically significant PFS benefit (p < 0.05), which was further supported by significantly prolonged investigator-assessed PFS (6.6 vs. 1.9 months; HR: 0.53; p = 0.0306). The most common grade 3 treatment-related adverse events (TRAEs) were hypertension (50%), proteinuria (15.2%), and thrombocytopenia (8.7%), with no grade 4/5 events. Considering the totality of the evidence and an acceptable safety profile, lucitanib may confer a meaningful clinical benefit for patients with advanced thymic carcinoma, warranting further investigation.

PMID 42928801
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lamotrigine orally disintegrating tablet